Abcentra

Oxford Initiates European Enrollment for FORTIFY Trial Testing Orticumab in Post-Heart Attack Inflammation

- Oxford University has recruited the first European participant for the FORTIFY clinical trial, testing orticumab, a monoclonal antibody targeting coronary inflammation in post-heart attack patients. - The international study, sponsored by Abcentra, will enroll approximately 240 participants across the United States and Europe who have elevated coronary inflammation measured by the Oxford-developed FAI score. - Orticumab works by binding to oxidized low-density lipoprotein to reduce arterial inflammation, representing a novel therapeutic approach for cardiovascular risk reduction. - The trial utilizes Oxford's proprietary fat attenuation index technology, which has become a clinically validated biomarker for heart attack risk assessment worldwide.